Interim analysis of effectiveness of JN.1-adapted conventional and self-amplifying mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infection in adults aged ≥60 years, Japan, October 2024–April 2025

2026/07/25 by Haruka Maeda, Ataru Igarashi, Shinya Mitsui +11

paper · doi:10.1016/j.vaccine.2026.128964